Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders
Abboud H., Salazar-Camelo A., George N., Planchon SM., Matiello M., Mealy MA., Goodman A., Alroughani R., Altintas A., Apiwattanakul M., Asgari N., Paolilo RB., Bennett J., Bichuetti DB., Blaschke TF., Boyko A., Broadley S., Contentti EC., Cohen JA., Delgado-Garcia G., Basuroski ID., Flores-Rivera J., Fujihara K., Havla J., Hellwig K., Hor JY., Huda S., Iorio R., Jarius S., Kimbrough D., Kister I., Kleiter I., Kissani N., Lana-Peixoto M., Leite MI., Levy M., Maiga Y., Mao-Draayer Y., Mariotto S., Melamed E., Neubrand VE., Oreja-Guevara C., Palace J., Pröbstel AK., Qian P., Quan C., Riley C., Ringelstein M., Sa MJ., Siritho S., Smith TJ., de Castillo IS., Tenembaum S., Villoslada P., Wuerfel J., Wingerchuk D., Yamout B., Yeaman M.
Neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune inflammatory conditions that primarily target the optic nerves, spinal cord, brainstem, and occasionally the cerebrum. NMOSD is characterized by recurrent attacks of visual, motor, and/or sensory dysfunction that often result in severe neurological deficits. In recent years, there has been a significant progress in relapse treatment and prevention but the residual disability per attack remains high. Although symptomatic and restorative research has been limited in NMOSD, some therapeutic approaches can be inferred from published case series and evidence from multiple sclerosis literature. In this review, we will discuss established and emerging therapeutic options for symptomatic treatment and restoration of function in NMOSD. We highlight NMOSD-specific considerations and identify potential areas for future research. The review covers pharmacologic, non-pharmacologic, and neuromodulatory approaches to neuropathic pain, tonic spasms, muscle tone abnormalities, sphincter dysfunction, motor and visual impairment, fatigue, sleep disorders, and neuropsychological symptoms. In addition, we briefly discuss remyelinating agents and mesenchymal stem cell transplantation in NMOSD.